Market cap
$400 Mln
Revenue (TTM)
$73 Mln
P/E Ratio
--
P/B Ratio
5.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.9
-
Debt to Equity
1.6
-
Book Value
$0.8
-
EPS
$-0.7
-
Face value
--
-
Shares outstanding
72,590,994
10 Years Aggregate
CFO
$-463.76 Mln
EBITDA
$-712.87 Mln
Net Profit
$-713.70 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cellectis S.A. - ADR
| -14.2 | -0.1 | 11.4 | 201.1 | 33.7 | -23.1 | -17.9 |
|
BSE Sensex
| -11.1 | -2.1 | -8.9 | -7.5 | 6.6 | 9.1 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Cellectis S.A. - ADR
| 168.9 | -41.3 | 46.7 | -74.1 | -70.0 | 58.1 | 2.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cellectis S.A. - ADR
|
4.2 | 400.4 | 73.2 | -67.8 | -82.1 | -65.5 | -- | 5.1 |
| 19.5 | 1,205.0 | 0.0 | -167.9 | -- | -128.7 | -- | 5.6 | |
| 27.5 | 1,862.3 | 1,043.8 | 488.8 | -19.0 | 16 | 3.2 | 0.5 | |
| 12.6 | 2,213.0 | 550.0 | 458.1 | -3.3 | 45.9 | 4.9 | 1.8 | |
| 8.7 | 396.2 | 0.0 | -29.0 | -- | -20.4 | -- | 3.0 | |
| 13.0 | 891.5 | 106,763.2 | 5,307.0 | 5.8 | 2147 | 66.4 | 3.4 | |
| 3.0 | 585.2 | 3.2 | -198.4 | -4,800.7 | -166.3 | -- | 7.6 | |
| 18.0 | 424.8 | 4.7 | -109.7 | -- | -30.2 | -- | 1.3 | |
| 5.8 | 597.4 | 174.7 | -115.2 | 0.0 | -80.2 | -- | 4.3 | |
| 20.7 | 2,201.0 | 453.3 | -178.1 | -27.8 | -25.1 | -- | 3.2 |
Shareholding Pattern
View DetailsAbout Cellectis S.A. - ADR
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates... in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Address: 8, rue de la Croix Jarry, Paris, France, 75013 Read more
-
Co-Founder, CEO & Director
Dr. Andre Choulika Ph.D.
-
Co-Founder, CEO & Director
Dr. Andre Choulika Ph.D.
-
Headquarters
Paris
-
Website
FAQs for Cellectis S.A. - ADR
What is the current share price of Cellectis SA - ADR Today?
The share price of Cellectis SA - ADR is $4.15 (NASDAQ) as of 15-May-2026 10:29 EDT. Cellectis SA - ADR has given a return of 33.66% in the last 3 years.
What is the current PB & PE ratio of Cellectis SA - ADR?
Since, TTM earnings of Cellectis SA - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-7.14
|
6.38
|
|
2024
|
-4.46
|
1.25
|
|
2023
|
-1.74
|
2.07
|
|
2022
|
-0.98
|
0.82
|
|
2021
|
-4.24
|
1.65
|
What is the 52 Week High and Low of Cellectis SA - ADR?
The 52-week high and low of Cellectis SA - ADR are Rs 5.48 and Rs 1.33 as of 15-May-2026.
What is the market cap of Cellectis SA - ADR?
Cellectis SA - ADR has a market capitalisation of $ 400 Mln as on 12-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Cellectis SA - ADR?
Before investing in Cellectis SA - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.